Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Nov;40(11):4671-4674.
doi: 10.1007/s10067-021-05884-4. Epub 2021 Aug 24.

Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials

Dimitrios Patoulias  1 , Michael Doumas  2   3 , Christodoulos Papadopoulos  4 , Asterios Karagiannis  2
Affiliations
Meta-Analysis

Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials

Dimitrios Patoulias et al. Clin Rheumatol. 2021 Nov.

Abstract

Coronavirus disease-2019 (COVID-19) represents a global public health nightmare. The "cytokine storm," the most prominent underlying pathophysiologic mechanism of this disease, can theoretically be targeted at several stages. Janus kinase (JAK) inhibitors constitute a drug class that could ameliorate the inflammatory response and enhance antibody production. Herein, we aimed to evaluate the efficacy of JAK inhibitors in patients with COVID-19, performing the most updated relevant meta-analysis. We searched two major databases for randomized controlled trials (RCTs) enrolling adult patients with documented COVID-19 in the in-hospital setting, assigned either to JAK inhibitor treatment plus standard of care or standard of care alone. We set as primary efficacy outcome the endpoint of COVID-19 death on day 28 and as secondary efficacy composite outcome that of mechanical ventilation or initiation of extracorporeal membrane oxygenation (ECMO). We finally pooled data of interest from 4 RCTs in a total of 1338 subjects with documented COVID-19 infection, utilizing the following JAK inhibitors: baricitinib, ruxolitinib, tofacitinib, and nezulcitinib. Treatment with JAK inhibitor compared to control resulted in a significant reduction in the risk for COVID-19 death by 43%, while it also led to a significant decrease in the risk for mechanical ventilation or ECMO initiation by 36%. Herein, we demonstrate a clear benefit with JAK inhibitors added to standard of care in patients with COVID-19 in terms of risk reduction concerning major outcomes. Larger RCTs will elucidate their place in treatment armamentarium against COVID-19.

Keywords: COVID-19; Janus kinase inhibitor; Mechanical ventilation; Mortality.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effect of JAK inhibitors compared to control on the risk for COVID-19 death
Fig. 2
Fig. 2
Effect of JAK inhibitors compared to control on the risk for mechanical ventilation or ECMO initiation in the context of COVID-19
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, Pardo-Hernandez H, Rochwerg B, Lamontagne F, Han MA, Liu Q, Agarwal A, Agoritsas T, Chu DK, Couban R, Darzi A, Devji T, Fang B, Fang C, Flottorp SA, Foroutan F, Ghadimi M, Heels-Ansdell D, Honarmand K, Hou L, Hou X, Ibrahim Q, Khamis A, Lam B, Loeb M, Marcucci M, McLeod SL, Motaghi S, Murthy S, Mustafa RA, Neary JD, Qasim A, Rada G, Riaz IB, Sadeghirad B, Sekercioglu N, Sheng L, Sreekanta A, Switzer C, Tendal B, Thabane L, Tomlinson G, Turner T, Vandvik PO, Vernooij RW, Viteri-García A, Wang Y, Yao L, Ye Z, Guyatt GH, Brignardello-Petersen R, Qasim A, Martinez JPD, Cusano E. Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ. 2020;371:m4852. - PMC - PubMed
    1. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–2273. doi: 10.1056/NEJMra2026131. - DOI - PMC - PubMed
    1. Morris G, Bortolasci CC, Puri BK, Marx W, O’Neil A, Athan E, Walder K, Berk M, Olive L, Carvalho AF, Maes M. The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all? Cytokine. 2021;144:155593. doi: 10.1016/j.cyto.2021.155593. - DOI - PMC - PubMed
    1. Chen CX, Wang JJ, Li H, Yuan LT, Gale RP, Liang Y (2021) JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis [published online ahead of print, 2021 May 14]. Leukemia 2021:1–5. 10.1038/s41375-021-01266-6. - PMC - PubMed
    1. Wijaya I, Andhika R, Huang I, Purwiga A, Budiman KY, Bashari MH, Reniarti L, Roesli RMA. The use of Janus kinase inhibitors in hospitalized patients with COVID-19: systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021;11:100755. doi: 10.1016/j.cegh.2021.100755. - DOI - PMC - PubMed

Publication types

Substances